The European Commission has granted authorisations for uses of 4-(1,1,3,3-Tetramethylbutyl)phenol, ethoxylated (4-tert-OPnEO):

• 2 uses applied for by Wallac Oy (4 January 2033);
• 1 use applied for by Lonza Biologics Porriño SL (4 January 2033);
• 1 use applied for by Merck KGaA (4 January 2033);
• 1 use applied for by Merck Biodevelopment SAS (4 January 2030); 
• 1 use applied for by Roche Diagnostics GmbH (4 January 2026);
• 1 use applied for by Teva Baltics UAB (4 January 2033);
• 1 use applied for by Swords Laboratories Unlimited Company (4 January 2033); and
• 2 uses for Zoetis Belgium S.A. and Delpharm Biotech (4 January 2031) and 2 uses for Zoetis Belgium S.A. (4 January 2033).